To tackle the phenotypic heterogeneity of schizophrenia, data-driven methods are often
applied to identify subtypes of its symptoms and cognitive deficits. However, a systematic …

The delineation of cognitive subtypes of schizophrenia and bipolar disorder may offer a
means of determining shared genetic markers and neuropathology among individuals with …

Cognitive impairment is a well-recognized key feature of schizophrenia. Here we review the
evidence on (1) the onset and sensitive periods of change in cognitive impairment before …

Cannabidiol (CBD), a principal phytocannabinoid constituent, has demonstrated
antipsychotic properties in recent clinical trials. While it has also been suggested a …

Highlights•Drugs for schizophrenia are often based on dopamine blockade and have
serious side-effects.•Xanomeline/trospium may well herald the first non-dopamine based …

Background In the last decade, the kynurenine pathway (KP) has gained attention in the
pathogenesis of cognitive impairment in schizophrenia being at the croassroad between …

Objective: Pragmatics refers to the capacity to understand the speaker's meaning and thus to
appropriately engage in a conversation. This study aims at establishing the role of …

Background Most studies of neurocognitive functioning in Clinical High Risk (CHR) cohorts
have examined group averages, likely concealing heterogeneous subgroups. We aimed to …

The notion that schizophrenia is a neuroprogressive disorder is based on clinical perception
of cumulative impairments over time and is supported by neuroimaging and biomarker …

Schizophrenia is a chronic psychotic disease burdened by cognitive deficits which hamper
daily functioning causing disability and costs for society. Biological determinants underlying …